Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer
2016 · JAMA Oncology · 111 citations
https://doi.org/10.1001/jamaoncol.2016.4884
N
Nan Song
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
253
Papers
4.0K
Citations
31
h-index
83
i10-index
Nan Song is an academic researcher from Zhejiang Chinese Medical University. The author has contributed to research in topics: Childhood Cancer Survivors' Quality of Life & Epigenetics and DNA Methylation & HER2/EGFR in Cancer Research. The author has an h-index of 31, co-authored 216 publications.
ORCID: 0000-0002-9182-1060Papers by this author
worksIntegrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers
2017 · Scientific Reports · 103 citations
https://doi.org/10.1038/s41598-017-17031-8
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
2019 · Journal of Clinical Oncology · 78 citations
https://doi.org/10.1200/jco.19.00443
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
2019 · JNCI Journal of the National Cancer Institute · 55 citations
https://doi.org/10.1093/jnci/djz032
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
2019 · Breast Cancer Research · 44 citations
https://doi.org/10.1186/s13058-019-1196-y
Emerging nanotechnology for Alzheimer's disease: From detection to treatment
2023 · Journal of Controlled Release · 42 citations
https://doi.org/10.1016/j.jconrel.2023.07.004
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat